English Summary
Shandong Xinglu Biological Technology Co., Ltd. is indexed in the China Little Giant company database. The Chinese legal name is 山东兴鲁生物科技有限公司. The profile is associated with Shandong. The report is grouped under Biomedicine. Recognition context: 2022 4th batch. Chinese source report date: 2026-06-14. 3 public evidence links are available on this page or in the Chinese report. The English brief covers company profile, product direction, industry-chain role, patent and R&D signals, scale indicators and policy-material checkpoints, with internal links to the company page, Chinese source report and related topic hubs.
Report Snapshot
| Company | Shandong Xinglu Biological Technology Co., Ltd. |
| Region | Shandong |
| Industry | Biomedicine |
| Published | 2026-06-14 |
| Chinese report | Open |
Company and Recognition Snapshot
Shandong Xinglu Biological Technology Co., Ltd. is indexed as a national-level Little Giant enterprise in Shandong. The English profile places the company under Biomedicine and records 2022 4th batch as the available recognition context.
| Recognition batch | 2022 4th batch |
| Region | Shandong |
| Industry | Biomedicine |
| Registered capital | RMB 16.22 million |
| Employee signal | 167 employees |
| Listed status | Not listed |
| Patent signal | 27 patent-related records |
| R&D signal | R&D investment detail not published in the English dataset |
Business and Industry-chain Position
Chinese public records indicate medical-device or biomedicine activity, new-materials activity, R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.
Technology, Patent and R&D Signals
The public profile records 27 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.
Policy-material Review Points
- Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
- Check that patent, R&D, employee and financial fields support the same core product direction.
- Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
- Use the linked Chinese source report for original-language evidence and source links.
Original Report and Profile
For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.